The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases
Open accessAbstract
A role for NK cells in therapeutic intervention for hematologic malignancies, such as acute myeloid leukemia and multiple myeloma, and nonhematologic malignancies, such as melanoma, is becoming more apparent. DNAM-1 is an NK cell receptor whose importance in facilitating activation signals received by NK cells in natural and cytokine-driven responses to tumor metastases in vivo is poorly explored. In this study, we used matched tumor lines expressing a variety of relevant ligands, neutralizing monoclonal Abs, and DNAM-1 gene-targeted mice to determine the relative importance of DNAM-1–ligand interactions in controlling tumor metastases. Our results demonstrate that NK cells require DNAM-1 for natural or cytokine (IL-2, IL-12, or IL-21) suppression of tumor metastases or their variants expressing CD70 or CD80. In contrast, DNAM-1 was dispensable when tumor cells were targets of Ab-dependent cellular cytotoxicity or presented ligands for NKG2D. CD155 appeared to be a key ligand recognized by DNAM-1 in NK cell-mediated suppression of metastases, and DNAM-1-mediated suppression coincided with perforin activity. Overall, these data implied a general role for DNAM-1-CD155 interactions in NK cell-mediated killing of tumors, even in the presence of tumor CD70 or CD80 expression, and further defined the optimal efficacy requirements of cytokines that directly activate NK cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity
Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903474106 · Cited by 3,524
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity
Diefenbach, A., Jensen, E. R., Jamieson, A. M., & Raulet, D. H. (2001) · Nature · doi:10.1038/35093109 · Cited by 1,083
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Diefenbach, A., Jamieson, A. M., Liu, S. D., Shastri, N., & Raulet, D. H. (2000) · Nature Immunology · doi:10.1038/77793 · Cited by 878
Lakshmikanth, T., Burke, S., Ali, T. H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci36022 · Cited by 347
Carlsten, M., Björkström, N. K., Norell, H., Bryceson, Y., van Hall, T., Baumann, B. C., Hanson, M., Schedvins, K., Kiessling, R., Ljunggren, H.-G., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2264 · Cited by 234
Research works printed but not linked: 48
- Kärre, 1986, Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy., Nature, 319, 675, 10.1038/319675a0 · DOI · Paper page
- Smyth, 1999, Perforin is a major contributor to NK cell control of tumor metastasis., J. Immunol., 162, 6658, 10.4049/jimmunol.162.11.6658 · DOI · Paper page
- Velardi, 2008, Role of KIRs and KIR ligands in hematopoietic transplantation., Curr. Opin. Immunol., 20, 581, 10.1016/j.coi.2008.07.004 · DOI
- Velardi, 2008, Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation., Semin. Immunopathol., 30, 489, 10.1007/s00281-008-0136-1 · DOI
- Davis, 2009, Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial., Clin. Cancer Res., 15, 2123, 10.1158/1078-0432.CCR-08-2663 · DOI
- Miller, 2005, Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer., Blood, 105, 3051, 10.1182/blood-2004-07-2974 · DOI · Paper page
- Romagne, 2009, Pre-clinical characterization of 1-7F9, a novel human anti-KIR therapeutic antibody that augments NK-mediated killing of tumor cells, Blood, 114, 2667, 10.1182/blood-2009-02-206532 · DOI · Paper page
- Bryceson, 2006, Activation, coactivation, and costimulation of resting human natural killer cells., Immunol. Rev., 214, 73, 10.1111/j.1600-065X.2006.00457.x · DOI · Paper page
- Shibuya, 1996, DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes., Immunity, 4, 573, 10.1016/S1074-7613(00)70060-4 · DOI · Paper page
- Dardalhon, 2005, CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions., J. Immunol., 175, 1558, 10.4049/jimmunol.175.3.1558 · DOI
- Seth, 2009, Heterogeneous expression of the adhesion receptor CD226 on murine NK and T cells and its function in NK-mediated killing of immature dendritic cells., J. Leukoc. Biol., 86, 91, 10.1189/jlb.1208745 · DOI
- Bottino, 2003, Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule., J. Exp. Med., 198, 557, 10.1084/jem.20030788 · DOI · Paper page
- Castriconi, 2004, Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction., Cancer Res., 64, 9180, 10.1158/0008-5472.CAN-04-2682 · DOI · Paper page
- Fuchs, 2004, Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)., J. Immunol., 172, 3994, 10.4049/jimmunol.172.7.3994 · DOI · Paper page
- Tahara-Hanaoka, 2006, Tumor rejection by the poliovirus receptor family ligands of the DNAM-1 (CD226) receptor., Blood, 107, 1491, 10.1182/blood-2005-04-1684 · DOI
- El-Sherbiny, 2007, The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells., Cancer Res., 67, 8444, 10.1158/0008-5472.CAN-06-4230 · DOI · Paper page
- Pende, 2006, Expression of the DNAM-1 ligands, Nectin-2 (CD112) and poliovirus receptor (CD155), on dendritic cells: relevance for natural killer-dendritic cell interaction., Blood, 107, 2030, 10.1182/blood-2005-07-2696 · DOI · Paper page
- Bryceson, 2006, Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion., Blood, 107, 159, 10.1182/blood-2005-04-1351 · DOI · Paper page
- Raulet, 2003, Roles of the NKG2D immunoreceptor and its ligands., Nat. Rev. Immunol., 3, 781, 10.1038/nri1199 · DOI · Paper page
- Hayakawa, 2002, Cutting edge: tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin., J. Immunol., 169, 5377, 10.4049/jimmunol.169.10.5377 · DOI · Paper page
- Moretta, 2001, Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis., Annu. Rev. Immunol., 19, 197, 10.1146/annurev.immunol.19.1.197 · DOI · Paper page
- Kelly, 2002, Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection., Nat. Immunol., 3, 83, 10.1038/ni746 · DOI · Paper page
- Kelly, 2002, A role for IFN-γ in primary and secondary immunity generated by NK cell-sensitive tumor-expressing CD80 in vivo., J. Immunol., 168, 4472, 10.4049/jimmunol.168.9.4472 · DOI
- Gilfillan, 2008, DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors., J. Exp. Med., 205, 2965, 10.1084/jem.20081752 · DOI · Paper page
- Street, 2001, Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis., Blood, 97, 192, 10.1182/blood.V97.1.192 · DOI · Paper page
- Ho, 2002, Costimulation of multiple NK cell activation receptors by NKG2D., J. Immunol., 169, 3667, 10.4049/jimmunol.169.7.3667 · DOI
- Smyth, 2001, NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma., Int. Immunol., 13, 459, 10.1093/intimm/13.4.459 · DOI · Paper page
- Street, 2007, Host perforin reduces tumor number but does not increase survival in oncogene-driven mammary adenocarcinoma., Cancer Res., 67, 5454, 10.1158/0008-5472.CAN-06-4084 · DOI
- Smyth, 2001, Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon γ-dependent natural killer cell protection from tumor metastasis., J. Exp. Med., 193, 661, 10.1084/jem.193.6.661 · DOI · Paper page
- Smyth, 2000, The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent., J. Immunol., 165, 2665, 10.4049/jimmunol.165.5.2665 · DOI · Paper page
- Brady, 2004, IL-21 induces the functional maturation of murine NK cells., J. Immunol., 172, 2048, 10.4049/jimmunol.172.4.2048 · DOI · Paper page
- Tahara-Hanaoka, 2004, Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112)., Int. Immunol., 16, 533, 10.1093/intimm/dxh059 · DOI · Paper page
- Smyth, 2004, NKG2D recognition and perforin effector function mediate effective cytokine immunotherapy of cancer., J. Exp. Med., 200, 1325, 10.1084/jem.20041522 · DOI · Paper page
- Chambers, 1996, Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1), Immunity, 5, 311, 10.1016/S1074-7613(00)80257-5 · DOI · Paper page
- Takeda, 2000, CD27-mediated activation of murine NK cells., J. Immunol., 164, 1741, 10.4049/jimmunol.164.4.1741 · DOI
- Rosenberg, 2001, Progress in human tumour immunology and immunotherapy., Nature, 411, 380, 10.1038/35077246 · DOI · Paper page
- Skak, 2008, Interleukin 21: combination strategies for cancer therapy., Nat. Rev. Drug Discov., 7, 231, 10.1038/nrd2482 · DOI
- Bryceson, 2009, Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors., Blood, 114, 2657, 10.1182/blood-2009-01-201632 · DOI · Paper page
- Pende, 2005, Analysis of the receptor-ligand interactions in the natural killer-mediated lysis of freshly isolated myeloid or lymphoblastic leukemias: evidence for the involvement of the Poliovirus receptor (CD155) and Nectin-2 (CD112)., Blood, 105, 2066, 10.1182/blood-2004-09-3548 · DOI · Paper page
- Halfteck, 2009, Enhanced in vivo growth of lymphoma tumors in the absence of the NK-activating receptor NKp46/NCR1., J. Immunol., 182, 2221, 10.4049/jimmunol.0801878 · DOI · Paper page
- Carlsten, 2009, Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells., J. Immunol., 183, 4921, 10.4049/jimmunol.0901226 · DOI · Paper page
- Verhoeven, 2008, NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways., Mol. Immunol., 45, 3917, 10.1016/j.molimm.2008.06.016 · DOI
- Toutirais, 2009, DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells., Eur. J. Immunol., 39, 1361, 10.1002/eji.200838409 · DOI
- Thompson, 2008, Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma., J. Clin. Oncol., 26, 2034, 10.1200/JCO.2007.14.5193 · DOI · Paper page
- Davis, 2007, An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma., Clin. Cancer Res., 13, 3630, 10.1158/1078-0432.CCR-07-0410 · DOI · Paper page
- Kim, 2006, FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma., Blood, 108, 2720, 10.1182/blood-2006-01-009480 · DOI · Paper page
- Yu, 2009, The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells., Nat. Immunol., 10, 48, 10.1038/ni.1674 · DOI · Paper page
- Baury, 2003, Identification of secreted CD155 isoforms., Biochem. Biophys. Res. Commun., 309, 175, 10.1016/S0006-291X(03)01560-2 · DOI
Cited by
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Self-citationZitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Self-citationNatural killer cells in cancer biology and therapy
Wu, S.-Y., Fu, T., Jiang, Y.-Z., & Shao, Z.-M. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01238-x · Cited by 863
Activating and inhibitory receptors of natural killer cells
Pegram, H. J., Andrews, D. M., Smyth, M. J., Darcy, P. K., & Kershaw, M. H. (2011) · Immunology & Cell Biology · doi:10.1038/icb.2010.78 · Cited by 555
Self-citationThe receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions
Chan, C. J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M. T., Town, L., Ritchie, D. S., Colonna, M., Andrews, D. M., & Smyth, M. J. (2014) · Nature Immunology · doi:10.1038/ni.2850 · Cited by 492
Self-citation
Metadata
- Authors
- Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita, H., Gilfillan, S., Colonna, M., & Smyth, M. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-12-27
- Volume
- 184
- Issue
- 2
- Pages
- 902-911
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2118653920
- Cited by
- 180
- References
- 8
- FWCI
- 3.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases. https://app.cochat.ai/papers/10.4049/jimmunol.0903225
- The paper
- Chan, C. J., Andrews, D. M., McLaughlin, N. M., Yagita, H., Gilfillan, S., Colonna, M., & Smyth, M. J. (2010). DNAM-1/CD155 Interactions Promote Cytokine and NK Cell-Mediated Suppression of Poorly Immunogenic Melanoma Metastases. The Journal of Immunology. https://doi.org/10.4049/jimmunol.0903225
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.